<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="627">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04365530</url>
  </required_header>
  <id_info>
    <org_study_id>Cohorte COVID GHPSJ CiteH</org_study_id>
    <nct_id>NCT04365530</nct_id>
  </id_info>
  <brief_title>Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City</brief_title>
  <acronym>COVIDGHPSJCite</acronym>
  <official_title>Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Paris Saint Joseph</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Paris Saint Joseph</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ongoing Coronavirus (Covid-19) pandemic is causing a major global health crisis and is
      shaking up hospital organizations. To date, the recognized risk factors for severe forms of
      Covid-19 infection are elderly patients (&gt; 70 years), obese patients, patients with chronic
      renal or respiratory pathologies, cardiovascular history (stroke or coronary artery disease),
      chronic respiratory conditions, high blood pressure, diabetes, and cancer. Covid-19 is
      manifested by a risk of acute respiratory distress syndrome requiring management by invasive
      ventilation. The lethality of this infection is around 4% in the current data.

      Drastic precautionary measures for the transmission of the virus, as well as the provision of
      critical care beds by canceling any scheduled non-urgent intervention or consultation, have
      shaken up the hospital organization.

      In this context, it is essential to have forward-looking data in real time to adjust the care
      offer and better understand the impact of Covid-19 on the patient populations treated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical consequences of a Covid-19 infection in the care population</measure>
    <time_frame>Year 2</time_frame>
    <description>This outcome measures the clinical consequences of a Covid-19 infection in the care population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk factors at M6</measure>
    <time_frame>Month 6</time_frame>
    <description>This outcome evaluates the risk factors of COVID-19 at month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors at year 1</measure>
    <time_frame>Year 1</time_frame>
    <description>This outcome evaluates the risk factors of COVID-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors at year 2</measure>
    <time_frame>Year 2</time_frame>
    <description>This outcome evaluates the risk factors of COVID-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of hospital reorganization on medical care at M6</measure>
    <time_frame>Month 6</time_frame>
    <description>This outcome evaluates the impact of hospital reorganization on medical care at month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of hospital reorganization on medical care at Year 1</measure>
    <time_frame>Year 1</time_frame>
    <description>This outcome evaluates the impact of hospital reorganization on medical care at year 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of hospital reorganization on medical care at Year 2</measure>
    <time_frame>Year 2</time_frame>
    <description>This outcome evaluates the impact of hospital reorganization on medical care at year 2.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>COVID</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patientwith symptoms compatible with infection by Covid-19 treated at the GHPSJ or in one
        of the establishments in the Paris Plaisance hospital city.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patient (of all ages) with symptoms compatible with infection by Covid-19 treated at the
        GHPSJ or in one of the establishments in the Paris Plaisance hospital city.

        Exclusion Criteria:

          -  Asymptomatic patient

          -  Patient objecting to the use of their data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit PILMIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Paris Saint Joseph</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benoit PILMIS, MD</last_name>
    <phone>144127820</phone>
    <email>bpilmis@hpsj.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helene BEAUSSIER, PharmD, pHD</last_name>
    <phone>144127883</phone>
    <phone_ext>+33</phone_ext>
    <email>crc@hpsj.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Marie Lannelongue</name>
      <address>
        <city>Le Plessis-Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien Hascoet, MD</last_name>
      <email>s.hascoet@hml.fr</email>
    </contact>
    <investigator>
      <last_name>Sebastien HASCOET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AURA Paris Plaisance</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime TOUZOT, MD</last_name>
      <email>maxime.touzot@auraparis.org</email>
    </contact>
    <investigator>
      <last_name>Maxime TOUZOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Sainte-Marie</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Bonte, MD</last_name>
      <email>florence.bonte@idf.vyv3.fr</email>
    </contact>
    <investigator>
      <last_name>Florence Bonte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit PILMIS, MD</last_name>
      <phone>144127820</phone>
      <phone_ext>+33</phone_ext>
      <email>bpilmis@hpsj.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bellan</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard DURAND GASSELIN, MD</last_name>
      <email>bernard.durand-gasselin@fondationbellan.org</email>
    </contact>
    <investigator>
      <last_name>Bernard Durand Gasselin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

